ATR
AptarGroup, Inc.
ATR's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ATR overall, supported by stronger modeled upside and stronger fundamentals.
ATR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Healthy |
ATR's balance sheet is currently healthy, and its revenue, profitability and cash flow are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ATR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 23x | $142 | — |
| Cheap | 24x | $100 | -29% |
| Fair | 32x | $131 | -7.7% |
| Current | 34x | $142 | — |
| Expensive | 35x | $145 | +2.1% |
Historical ranges are pointers, not guarantees.
ATR has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ATR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ATR, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ATR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.08 | +48% |
| Q3 2026 | $4.12 | -34% |
| Q2 2026 | $5.53 | -4.7% |
| Q1 2026 | $5.84 | +6.8% |
| Q4 2025 | $5.89 | +6.5% |
| Q3 2025 | $6.24 | +25% |
| Q2 2025 | $5.80 | +22% |
| Q1 2025 | $5.47 | +17% |
| Q4 2024 | $5.53 | +30% |
ATR's earnings per share have fallen from their peak: $4.12 over the past year, against $6.24 in late 2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ATR on earnings, with more consistent year-over-year improvement.
ATR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +6% |
| Q2 2026 | $1B | +6.3% |
| Q1 2026 | $982.9M | +11% |
| Q4 2025 | $962.7M | +14% |
| Q3 2025 | $961.1M | +5.7% |
| Q2 2025 | $966M | +6.1% |
| Q1 2025 | $887.3M | -3.1% |
| Q4 2024 | $848.1M | +1.1% |
ATR's revenue has grown year over year for six quarters in a row: $1B last quarter, up 6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -1 points |
| Q2 2026 | 12% | -2.6 points |
| Q1 2026 | 11% | -1.8 points |
| Q4 2025 | 11% | -3.1 points |
| Q3 2025 | 14% | -1 points |
| Q2 2025 | 15% | +1.1 points |
| Q1 2025 | 13% | +0.5 points |
| Q4 2024 | 14% | +4.1 points |
ATR's operating margin was 13% last quarter, down 1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ATR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ATR on profitability, with a higher operating margin.
ATR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $98.6M | -14% |
| Q2 2026 | $45.9M | -27% |
| Q1 2026 | $53.3M | +106% |
| Q4 2025 | $96.9M | -14% |
| Q3 2025 | $114.3M | -30% |
| Q2 2025 | $62.5M | -17% |
| Q1 2025 | $25.9M | +55% |
| Q4 2024 | $112.2M | -19% |
ATR's free cash flow has been positive every quarter for seven years: $295M over the past year, down 6.4% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ATR on cash flow, with more consistent year-over-year improvement.
ATR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -61K shares |
| 1 year | -3.7% | -2.5M shares |
| 3 years | -4.3% | -2.9M shares |
| 5 years | -5.4% | -3.7M shares |
| Available history | -3.1% | -2M shares |
ATR has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $30M |
| Q2 2026 | $50M |
| Q1 2026 | $100M |
| Q4 2025 | $175M |
| Q3 2025 | $40M |
| Q2 2025 | $70M |
| Q1 2025 | $80M |
| Q4 2024 | $37.3M |
ATR spent $355M buying back its own shares over the past year, up 56% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ATR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.2x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.1x | Healthy |
ATR's net debt is about 1.5 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over ATR on leverage, with a lower net debt burden relative to earnings.
ATR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.9 | Neutral |
| Stochastic | 78.5 | Neutral |
ATR's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ATR PE vs Healthcare Sector
| Metric | ATR | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 33% above |
| PE % | 80 | 29 | 51 pts above |
ATR has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ATR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $129.6 | 9.4% above |
| 20 week MA | $130.0 | 9% above |
| 50 week MA | $127.1 | 11% above |
| 100 week MA | $135.9 | 4.3% above |
| 200 week MA | $135.3 | 4.8% above |
ATR is in an uptrend: it's above all five of its weekly moving averages, and 4.8% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ATR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $115.0 | $135.7 | +18% |
| 2021 | $135.7 | $116.3 | -14% |
| 2022 | $116.3 | $110.0 | -5.4% |
| 2023 | $110.0 | $123.6 | +12% |
| 2024 | $123.6 | $158.2 | +28% |
| 2025 | $158.2 | $123.3 | -22% |
| 2026 YTD | $123.3 | $141.7 | +15% |
ATR has finished lower in three of the last six years. It's up 15% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ATR on returns for 2026, with the stronger performance.